Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (318)	6/16/1998 2:19:00 PM
From: Barron Von Hymen	Read Replies (1) \| Respond to of 1722

Another advantage of Big Pharma is not only do they have the resources and expertise to develop a drug and risk taking it so far into development and market it, but also they have the expertise in the organization, and the proven ability to move a drug through clinical trials smoothly and successfully. this is so important b/c there are many many decision points to be made at every stage in clinical development that may affect the whole outcome of the drug development! This is very lacking in a small biotech without that experience. Even if they have a great drug, if they can't get backing from big pharma to help them with the clinical trials, they are 3$@$ out of luck. Better to bet on PFE than ICOS or Harvard Scientific.